Pfizer Inc. expects more generic competition for its established drugs in 2017, and the company’s deal-making to gain products may continue to thrive. After posting fourth-quarter earnings and a forecast that were short of analysts’ estimates, New York-based Pfizer said it would continue to pursue deals, regardless of their size, as long as they create shareholder value.